TRACEY WIESE: Open Payments
NPI 1467781021 · ANCHORAGE, AK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$510 in 22 payments from 10 companies in 2025. Trend: 2023 $97 · 2024 $319 · 2025 $510
Food & beverage: $510
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 6 | $164 |
| ABBVIE INC. | 3 | $76 |
| Gilead Sciences, Inc. | 2 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| ViiV Healthcare Company | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: Qelbree, VRAYLAR, INGREZZA, TRINTELLIX, Jornay PM, REXULTI, CAPLYTA, COBENFY.
Industry payments across AK — which companies pay providers there.
